Singular Genomics Systems Receivables 2020-2024 | OMIC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Singular Genomics Systems receivables from 2020 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Singular Genomics Systems receivables from 2020 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$93.4B
Cencora (COR)	$48.3B
DiDi Global (DIDIY)	$22.2B
Natera (NTRA)	$22.1B
ICON (ICLR)	$17.7B
Viatris (VTRS)	$16B
Avantor (AVTR)	$14.1B
Revvity (RVTY)	$13.6B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.2B
BioMerieux (BMXMF)	$11.9B
Medpace Holdings (MEDP)	$10.5B
Charles River Laboratories (CRL)	$10B
HealthEquity (HQY)	$9.1B
Doximity (DOCS)	$9B
Sonic Healthcare (SKHHY)	$8.9B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Organon (OGN)	$3.9B
Sotera Health (SHC)	$3.6B
BrightSpring Health Services (BTSG)	$3.3B
Surgery Partners (SGRY)	$2.9B
Concentras Parent (CON)	$2.8B
PACS (PACS)	$2.5B
Alignment Healthcare (ALHC)	$2.3B
Ardent Health Partners (ARDT)	$2.3B
Premier (PINC)	$2.2B
GeneDx Holdings (WGS)	$2.2B
Ryman Healthcare (RYHTY)	$2B
GoodRx Holdings (GDRX)	$1.9B